Haemonetics HAE Ratios & Valuation
| FY'26 | FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 59%+4.0pp | 55%+2.2pp | 52.8%+0.2pp | 52.6%+1.7pp | |
| Efficiency | |||||
| Asset turnover | 0.6×0.0× | 0.6×0.0× | 0.6×0.0× | 0.6×+0.1× | |
| Liquidity | |||||
| Current ratio | 3×+1.3× | 1.6×-0.9× | 2.6×-0.5× | 3.1×+1.3× | |
| Leverage | |||||
| Debt-to-equity | 1.6×0.0× | 1.6×+0.7× | 0.9×-0.1× | 1×-0.1× | |
| Per Share | |||||
| Book value per share | $16.82+3.9% | $16.18-13.4% | $18.68+17.4% | $15.91+9.0% | |
| Valuation | |||||
| Market capitalization | $2.62B-18.0% | $3.19B-26.3% | $4.33B+3.8% | $4.17B+29.2% | |
| Price / sales | 2×-0.4× | 2.3×-1.0× | 3.3×-0.3× | 3.6×+0.3× | |
| Price / book | 3.3×-0.6× | 3.9×-0.6× | 4.5×-0.6× | 5.1×+0.8× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Haemonetics's profit margins?
- Haemonetics (HAE) runs a 59.0% gross margin and a 19.0% operating margin, with a 13.3% net margin.
- Where do Haemonetics's ratios come from?
- Every ratio is computed from Haemonetics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.